Overview

A Study Evaluating S 95005 Plus Bevacizumab and Capecitabine Plus Bevacizumab in Patients With Previously Untreated Colorectal Cancer Who Are Non-eligible for Intensive Therapy

Status:
Completed

Trial end date:
2020-09-01

Target enrollment:

Participant gender:

Summary

The main purpose of this study is to evaluate the progression-free survival (PFS) in patients receiving S 95005 + bevacizumab (experimental arm) or capecitabine + bevacizumab (control arm) as first-line treatment for unresectable metastatic colorectal cancer in patients non-eligible for intensive therapy.

Phase:

Phase 2

Details

Lead Sponsor:

Institut de Recherches Internationales Servier

Collaborator:

ADIR, a Servier Group company

Treatments:

Bevacizumab
Capecitabine
Trifluridine